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ABSTRACT
Objectives: Recent decades have witnessed the
development of highly innovative new antiviral drug
therapies. However, there are concerns that rising costs
and lengthening development times could have
implications for future patient access to innovative new
drugs. We sought to establish whether the time taken
for the clinical development of new antiviral drugs
launched in the UK had increased since the 1980s.
Design and setting: Retrospective observational
study of all new antiviral drugs licensed for use in
the UK.
Primary and secondary outcome measures:
Duration of clinical development (from initiation of
studies in humans to receipt of Marketing
Authorisation), subdivided into clinical trial and
regulatory approval periods by the date of Marketing
Authorisation Application.
Results: 48 new antiviral drugs were licensed for use
in the UK between 1981 and 2014 (inclusive), over half
(54%) initially for HIV infection. The overall mean
duration of clinical development was 77.2 months, of
which 64.6 months was spent in clinical trials before
regulatory submission. The total time in clinical
development increased from 41.7 months for drugs
licensed 1981–1992 to 91.7 months for drugs licensed
2004–2014. This increase was accounted for by an
increase in the clinical trials period and not the
regulatory approval period, for which there was no
observable trend. Drugs initially licensed to treat
hepatitis C had a longer duration of clinical
development than those indicated for other viral
infections. However, the, initially shorter clinical
development durations of drugs indicated for HIV
infection increased more rapidly across the study
period than those indicated for other viral infections.
Conclusions: The time spent by antiviral drugs in
clinical development has increased markedly in recent
decades despite many initiatives to speed access to
innovative new drugs. However, this represents only
one part of the translational research pathway, and a
complete picture of development timeframes is lacking.
INTRODUCTION
Recent decades have seen the emergence
and identiﬁcation of several new viral
infections of global signiﬁcance,1 2 but they
have also witnessed the development of
highly innovative new antiviral drug therapies,
which have, for example, dramatically
improved the prognosis of those infected with
HIV3 and now are radically changing the care
of those infected by hepatitis C.4 However,
concerns have been expressed about the
increasing costs of developing new drugs and
bringing them into clinical use.5–9 In broad
terms, drug development begins with discov-
ery and preclinical laboratory research,
before moving on to clinical development,
starting with ﬁrst testing in humans (phase I
clinical trials) and continuing until regulatory
review and approval.5 6 10 11 Phase I to III clin-
ical trials may be responsible for more than
half the time and cost required to bring a new
drug from discovery to regulatory approval.6 12
Therefore, trends in the time taken for clin-
ical development may be an important driver
of increasing total development costs as well
as having implications for patient access to
innovative new medicines.
Strengths and limitations of this study
▪ This is the most up to date and complete study
that considers trends in clinical development
timelines for new drugs introduced into the UK.
▪ The study used data from the European
Medicines Agency, Medicines and Healthcare
Products Regulatory Agency and British National
Formulary to ensure that all relevant drugs were
identified and regulatory dates were accurate.
▪ However, this study considered only the clinical
phase of development, from the initiation of clin-
ical trials to regulatory approval and omits the
time and resources needed for discovery and
preclinical development, as well as postauthori-
sation activities.
▪ This study did not consider new indications or
the repurposing of existing licensed and mar-
keted drugs.
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A number of authors have attempted to characterise
the time taken to translate basic research ﬁndings into
clinical practice; a review by Morris et al10 identiﬁed a
number of studies reporting the time taken to translate
health research, concluding that 17 years was the most
likely estimate despite wide variation in deﬁnitions and
marked differences in the time periods studied and
approaches to data collection. However, few researchers
have considered trends in drug development time-
frames. Keyhani et al13 considered the time taken from
the Investigational New Drug (IND) Application (a step
required by the US Food and Drug Administration
(FDA) prior to testing in humans14) to the ﬁling of a
New Drug Application15 and subsequent FDA approval
(the latter time points representing the regulatory
review process). For all new drugs approved in the USA
from 1992 to 2001, the authors found no increase in the
time taken to conduct clinical trials prior to ﬁling a New
Drug Application (median 5.1 years) and a decrease in
the time taken for the subsequent regulatory review and
approval. Kaitin and DiMasi16 considered a much longer
time frame (1980–2009) and also found a decrease in
time taken for regulatory review by the FDA. However,
they found an increase in the clinical trial periods prior
to ﬁling (increasing from a mean 5.7 years for drugs
approved in the USA 1980–1984, to 6.4 years for those
approved 2005–2009) and concluded that this was due,
in part, to increasing numbers of central nervous system
and antineoplastic agents with very long average devel-
opment times. However, the clinical trial periods prior
to ﬁling (ie, from IND application to ﬁling a New Drug
Application) for HIV antiviral agents also increased from
a mean 2.3–5 years, and clinical trial periods for other
anti-infective agents (including other antiviral drugs)
increased from 4.2 to 6.6 years. More recent data on
drug intervention trials registered with ClinicalTrials.gov
suggests that trial lengths may have reduced in recent
years (from 2 years for trials beginning in 2005 to
1.3 years for those beginning in 2009), but this trend
was considerably less marked for industry sponsored
trials, which are more likely to support the approval of
new drugs.17
Similar data on trends in drug development have not
been published for drugs launched in the UK. We
sought to determine whether the overall time taken for
the clinical development (clinical trial periods prior to
ﬁling and subsequent consideration by the regulator) of
new drugs launched in the UK had changed over more
than three decades, using data for antiviral drugs.
METHODS
All new drugs ﬁrst licensed for use in the UK between
1981 and 2014 (inclusive) and speciﬁcally indicated for
the treatment of viral disease were identiﬁed along with
their initial approved indication(s) from relevant edi-
tions of the British National Formulary (BNF) and the
European Medicines Agency (EMA) website. The BNF
lists all preparations available for prescribing and/or dis-
pensing in the UK, including prescription only and
over-the-counter medicines. A new drug was deﬁned as a
new chemical entity or new biological product not previ-
ously licensed for use in the UK; new formulations and
new indications for existing licensed drugs were omitted
from the study, as were new combination products where
all the active components were already licensed and
available separately or in other combination products.
Clinical development was deﬁned as the period from
the initiation of studies in humans (clinical trials) to the
receipt of a Marketing Authorisation (MA or ‘licence’)
applicable to the UK from the Medicines and
Healthcare Products Regulatory Agency (MHRA) or the
EMA as appropriate.5 This period was further subdivided
by the date of Marketing Authorisation Application
(MAA, regulatory submission or ‘ﬁling’) into periods
representing clinical trials (prior to ﬁling) and subse-
quent regulatory approval. The initiation of clinical
development was determined from searches of a com-
mercial pharmaceutical R&D database (Pharmaprojects,
Informa Group plc) and a bibliographic database of
published biomedical literature (MEDLINE, US
National Library of Medicine). The date of IND
Application to the FDA was taken as the start of clinical
development; where this was not available, we used the
date that the ﬁrst clinical trials were undertaken (taken
from the published literature) or the date that the ﬁrst
report of clinical trials (typically phase I) was published
instead. The dates of MAA and MA were obtained from
the EMA website or direct from the MHRA.
The duration of clinical development, as well as the
clinical trial and regulatory approval periods, were calcu-
lated to the nearest month. Simple descriptive statistics
were used to summarise these data and explore differ-
ences in durations according to the drug indication
(viral disease) and year of licence (1981–1992, 1993–
2003 and 2004–2014). The statistical signiﬁcance of dif-
ferences in mean duration were determined using
unpaired t tests. Scatter plots were used to visualise
trends in development timeframes by year of UK drug
launch, and where relevant, Pearson’s correlation coefﬁ-
cient and least-squares linear regression lines were calcu-
lated. Statistical analyses were conducted using SPSS
(V.21.0, IBM).
RESULTS
There were 48 new drugs licensed for the treatment of
viral diseases in the UK during the 34-year period from
1981 to 2014, representing a mean 1.4 new drugs per
year (table 1). Almost half of these drugs were licensed
in the middle period (1993–2003, 48%), while just 15%
were licensed in the earlier period (1981–1992). Over
half of new drugs (54%) were initially indicated for HIV
infection. The next most frequent initial indication was
hepatitis C infection (15%), followed by infection with
cytomegalovirus (13%), hepatitis B (8%), herpes
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simplex virus (4%), inﬂuenza virus (4%) and respiratory
syncytial virus (2%, full details provided in online
supplementary ﬁle 1).
The overall mean duration of clinical development was
77.2 months, the majority of which was spent in clinical
trials before the date of regulatory submission (84%,
table 1). The total time in clinical development increased
during the study period, from 58 months for drugs
licensed 1981–1992, to 91.7 months for drugs licensed
2004–2014, a result that was statistically signiﬁcant
(p=0.048). This increase was accounted for by an
increase in time spent in clinical trials before regulatory
submission, which increased from 41.7 months for drugs
licensed 1981–1992 to 78.4 months for drugs licensed
2001–2014 (p=0.027). No equivalent increase in time
spent in the regulatory approval period was observed. A
statistically signiﬁcant upward linear trend in the total
duration of clinical development (r=0.31, y=1.26×year—
2442.01, p=0.034, ﬁgure 1) and the clinical trials period
(r=0.34, y=1.38×year—2695.37, p=0.018) was observed for
drugs licensed across the whole study period, suggesting
that mean total clinical development and clinical trial
durations increased by 12 months every 9.5 and 8.7-year
period, respectively. In contrast, no signiﬁcant linear
trend was observed for the duration of the regulatory
approval period (r=0.16, y=−0.12×year+253.36, p=0.32).
Considering the initial indications for new drugs,
those licensed to treat hepatitis C infection had a longer
duration of clinical development than those indicated
for HIV infection or other viral infections (table 1),
though this result was not statistically signiﬁcant. A statis-
tically signiﬁcant upward linear trend was observed for
total clinical development durations for drugs ﬁrst
licensed to treat HIV across the study period (r=0.54,
y=1.84×year—3606.44, ﬁgure 2). The clinical develop-
ment durations of drugs initially licensed to treat other
viral infections increased at a slower rate, and the trend
was not statistically signiﬁcant (r=0.29, y=0.98×year—
1882.40).
DISCUSSION
We have shown that for drugs licensed in the UK to
treat viral infections, the time spent in clinical develop-
ment has increased markedly over the past three
decades. This increase is due to increasing time spent in
clinical trials before regulatory submission; no trend was
observed in the time taken for regulatory approval. In
addition, drugs licensed for hepatitis C appeared to
spend longer in development than those for other viral
infections but clinical development durations increased
more rapidly for drugs licensed to treat HIV than those
licensed to treat other viral infections. Our estimate of
the rate of increase in mean time spent in clinical trials
prior to regulatory submission is much greater than that
found by Kaitin and DiMasi for all drugs approved in
the USA between 1980 and 2009 (from 5.7 years in the
period 1980–1989, to 6.4 years in the period 2000–
2009).16 However, a more appropriate comparison
might be between our results and those for anti-HIV
drugs and other anti-infectives, where Kaitin and DiMasi
reported a 117% and 57% increase, respectively, in the
mean time spent in clinical trials between the periods
1980–1989 and 2000–2009. Our estimates of the mean
time that antiviral drugs spent in clinical trials prior to
ﬁling increased 87% between the periods 1981–1992
and 2001–2014, and our estimated mean time spent in
clinical trials for the period 2004–2014 (6.5 years for all
antiviral drugs and 5.3 years for anti-HIV drugs) were
similar to those reported by Kaitin and DiMasi for the
period 2000–2009 (5 years for anti-HIV drugs and
6.6 years for other anti-infectives), showing a consider-
able degree of concurrence between their ﬁndings and
our own.
This study relied on data from the BNF, MHRA and
EMA, ensuring that the identiﬁcation of drugs was com-
prehensive and the data on regulatory dates were accur-
ate. For initiation of clinical trials, we relied on the date
of IND application, a process which only applies to the
USA and not to Europe. This point in the development
Table 1 Duration of clinical development for antiviral drugs, in total and subdivided into clinical trials and regulatory approval
periods, by year of first license and indication in the UK, 1981–2014
Number
Duration of development (months)
Clinical trials period
Regulatory approval
period Total duration
Mean SE 95% CI Mean SE 95% CI Mean SE 95% CI
All new drugs 48 64.6 4.70 55.9 to 73.3 12.6 0.96 10.8 to 14.7 77.2 4.75 68.7 to 86.6
Drugs licensed between
1981–1992 7 41.7 9.90 23.5 to 62.6 16.3 5.02 7.3 to 26.8 58.0 13.2 37.6 to 86.4
1993–2003 23 63.2 5.34 53.6 to 73.7 11.2 1.01 9.3 to 13.1 74.4 5.21 64.9 to 84.9
2004–2014 17 78.4 9.02 61.5 to 96.7 13.3 1.10 11.3 to 15.6 91.7 8.80 75.2 to 108.9
Initial licensed indication
HIV infection 26 55.8 4.18 47.5 to 64.1 11.8 0.94 10.0 to 13.5 67.6 4.43 58.7 to 76.5
Hepatitis C infection 7 92.1 20.52 52.8 to 133.4 13.9 4.69 8.4 to 25.2 106.0 21.00 63.7 to 147.2
Other viral infection 15 66.8 7.97 51.2 to 83.3 13.5 1.59 10.3 to 16.4 80.3 7.32 66.6 to 95.3
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of a new molecule occurs when the developer ‘wants to
test its diagnostic or therapeutic potential in humans’.14
On a global basis, the IND application may be regarded
as a reasonable proxy for the decision to advance
development of a new drug beyond preclinical testing
given that in recent decades the majority of new drugs
have been launched in the USA at an earlier or similar
time to Europe.18 The European Union (EU) equivalent
Figure 1 Duration of clinical development for antiviral drugs by year of first license in the UK, 1981–2014.
Figure 2 Duration of clinical development for antiviral drugs indicated for HIV and other viral infections by year of first license in
the UK, 1981–2014.
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process, requiring submission of a request for authorisa-
tion of clinical trials, stems from a 2001 Directive19 and
is therefore a more recent development that could not
be applied to the study period of interest. We could not
determine a date for IND application in six cases (repre-
senting drugs launched between 1982 and 1996). The
association between clinical development time and year
of launch was maintained after excluding these drugs
from the analysis (r=0.42, y=1.99×year—3912.46,
p=0.006).
Our study addresses only the clinical development
period of drug development; it omits the time and
resources needed to discover and bring a candidate mol-
ecule through laboratory and initial animal studies, and
does not consider activities postapproval, including mar-
keting, phase IV studies, evidence reviews and the gener-
ation of guidance to clinicians and health services.6 11 20
Several commentators have described models of the
translation pathway providing consistent deﬁnitions for
different stages of the process and allowing comparison
between studies and evaluation of efforts to reduce
unwarranted delays. Trochim et al11 proposed a ‘process
marker’ model that recognises translational research as
a continuous process that may be ‘bidirectional, variable,
(and) complex’ with observable milestones along a gen-
eralised pathway allowing measurement of time elapsed
between them. Recognising that the process marker
model may be more appropriate to technology driven
developments, Hanney et al20 have proposed a generalis-
able model for all healthcare innovation, suggesting a
matrix of four different ‘tracks’ in the innovation
process, building from discovery research, through
human research and research review, to clinical and
health service/public policy development and ﬁnally
clinical practice. This recognises the overlapping nature
of research translation activities, and allows for the initi-
ation of different tracks at different times despite rele-
vant research still occurring in ‘earlier’ tracks. Our study
considers the ‘Clinical Trials System’ element of the
translational research continuum described by Trochim
et al11 and overlapping elements of tracks 2 and 3 in
Hanney et al’s20 description of the innovation process.
Taken together, these help identify drivers of the trends
seen. In this way, the increasing demands of regulators
that have led to increasing complexity of clinical trial
programmes are highly relevant to the increase in clin-
ical trial periods we have observed. This has been recog-
nised by policymakers, who have agreed revisions to the
2001 EU Clinical Trials Directive (effective from 2004),
widely seen as having a negative impact on translational
research, increasing administrative burdens and waiting
periods21–24 and introduced a range of initiatives in the
USA and Europe to provide a more rapid pathway to
approval for innovative drugs that address serious condi-
tions, urgent public health needs or speciﬁc patient
groups.25 26
Despite the introduction of these initiatives, visual
inspection of our data (ﬁgures 1 and 2) shows no
apparent step change consistent with a sudden change
in the regulatory environment (such as the creation of
the EMA or implementation of the EU Clinical Trials
Directive). This may be expected given the long lead
times for planning and conducting clinical trial pro-
grammes, though further analysis shows no association
between the duration of clinical development and the
year when clinical development started (r=0.04, y=−0.16
+399.67, p=0.80). However, the impact of regulators can
be seen in the shorter development durations seen for
HIV drugs, which have previously been reported as
receiving Marketing Authorisation without ‘large-scale
human clinical trials’,27 though our data suggest this dif-
ference is now lessening. This is an example of regula-
tors responding to a public health need and being
willing to adopt a different view of the risk-beneﬁt in
speciﬁc circumstances.20 One current regulatory devel-
opment applicable to the UK is the MHRA’s Early
Access to Medicines Scheme, which allows patients with
serious conditions to access medicines that have not yet
been approved where there is a clear unmet medical
need.28 This will not necessarily reduce time to
Marketing Authorisation, but may facilitate collection of
real-world data to support earlier adoption of innovative
new drugs. In this way it has parallels with the EMA’s
adaptive licensing pilot, but this EU-wide initiative also
has the potential to bring forward the date of a drugs
initial Marketing Authorisation, allowing ﬁrst approval in
highly selected patient populations based on more
limited initial clinical studies.29 Both these examples are
indicative of a wider move towards early dialogue
between regulators and commercial developers,26 a
move mirrored by health technology assessment (HTA)
agencies in Europe, either alone or in parallel with regu-
lators.26 30 Early dialogue may or may not lead to a
reduction in clinical development durations, but it is
likely to be reﬂected in the design and conduct of late-
phase clinical trial programmes.30 31 This will have an
uncertain effect on clinical trial times if HTA agencies
demand longer term patient-related outcomes rather
than proxy measures on which to judge value, but it may
be expected to speed up the total time to adoption and
diffusion of those drugs judged to be most clinically and
cost-effective.
The past few decades have seen the introduction of
many novel antiviral drugs, but the time spent in clinical
development before drug approval has increased sub-
stantially. We found no evidence that this trend in
increasing clinical development timescales is levelling
off, though many of the current initiatives aimed to
speed access to innovative new medicines are too recent
to have affected clinical trial programmes for drugs
launched up to 2014, and will therefore require further
evaluation in the coming years. However, it is important
to stress that adequate time spent in clinical trials is crit-
ical to generate evidence of safety, efﬁcacy and cost-
effectiveness20 and that regulators require adequate time
to consider this evidence and strike an appropriate
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balance between beneﬁt and risk.32 There are necessar-
ily limits to clinical development durations, but this is
only one part of the whole discovery to clinical practice
translational pathway and increased time in one part of
the pathway may be offset by gains elsewhere. Further
research should incorporate measures of preclinical and
adoption timeframes in order to gain a complete
picture and ensure there are no unwarranted delays in
novel drugs reaching patients in need.
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